Abstract:e16010 Background: Preoperative therapy of esophageal squamous cell carcinoma (ESCC) is stepping into the era of combined therapy with PD-1 inhibitor after the success of PD-1 antibodies in the first-line and second-line treatment for advanced ESCC. This single center study retrospectively analyzed the efficacy and safety of preoperative chemotherapy combined with PD-1 antibody in patients with locally advanced operable or potentially resectable ESCC in the real world. Methods: The study enrolled operable or potentially resectable locally advanced ESCC patients treated with preoperative chemotherapy combined with PD-1 inhibitor in our center from April 2020 to December 2020. The treatment regimen were 2 to 4 cycles of paclitaxel liposome (135̃175 mg/m 2 ) or albumin paclitaxel (180mg/m 2 ) plus nedaplatin (75mg/m 2 ) or lobaplatin (30mg/m 2 ) combined with PD-1 inhibitors (toripalimab 13/20, sintilimab 3/20, pembrolizumab 2/20, camrelizumab 1/20, tislelizumab 1/20) with standard therapeutic dose followed by tumor response assessment and surgery. The primary end point were safety, tumor response and complete pathological response (pCR) rate. Results: A total of 20 patients including 17 males and 3 females, of which median age was 65 and 85% were stage III-IVA (AJCC 8 th ), were included in the study. Of all the patients, 18 patients accomplished 2 cycles of therapy and had safety assessment, 13 patients underwent surgery, 2 patients were waiting for operations and 2 patients achieving partial response rejected surgery and were prepared for radical chemoradiotherapy. Treatment-related adverse events exceeding grade 3 levels included leukopenia 5.6% (1/18), neutropenia 16.7% (3/18), thrombocytopenia 5.6% (1/18), and immune hepatitis 5.6% (1/18). There was no severe surgery-related complication. Objective response rate (ORR) was 70.6% (12/17), and disease control rate (DCR) was 100% (17/17). R0 resection rate was 92.3% (12/13), the pCR rate was 15.4% (2/13), and 61.5% (8/13) of the patients had downstaged to the ypT1-2N0M0 I stage. One patient finally reached a pCR after switching to preoperative chemoradiotherapy because of progression after treatment of chemotherapy and PD-1 inhibitor. Conclusions: Preoperative chemotherapy combined PD-1 inhibitor treatment was well tolerated and had high efficacy in locally advanced operable and potential resectable ESCC. Since the study included some potentially resectable patients with late staging, the pCR rate may be lowered. The further study aims to find the efficient biomarker including PD-L1 expression and CD8 + T cell infiltration. Moreover, well-designed randomized prospective trials for better evidence are required.

PVP Preoperative Inductive Chemotherapy in 764 Cases of Oral Squamous Cell Carcinoma

Intermediate and Long-Term Therapeutic Effect Analysis of Preoperative Induction Chemotherapy As Comprehensive Therapy in Healing Oral Squamous Cell Carcinoma

[The Use of Two-Route Cisplatin Chemotherapy in the Treatment of Oral Squamous Cell Carcinoma].

Comparison of Surgeries Plus Perioperative and Postoperative Chemotherapies in Chinese Pn2 Patients with Non-Small Cell Lung Cancer: A Real-World Observational Study.

Retrospective Analysis of 56 Patients with Advanced Gastric Cancer Treated with Combination of Intravenous and Intra-Arterial Intensified Neoadjuvant Chemotherapy

Neoadjuvant Chemotherapy for Locally Advanced Squamous Carcinoma of Oral Cavity: a Pilot Study

Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas

Effects of MVP regimen on operation and cancer tisswes of Lung Cancer patients.]

Efficacy and safety of vinorelbine and cisplatin regimen of different doses and intensities for neoadjuvant chemotherapy in patients with locally advanced esophageal carcinoma

Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real-world retrospective study

Anti-tumor Effect of Cisplatin in Human Oral Squamous Cell Carcinoma Was Enhanced by Andrographolide Via Upregulation of Phospho-P53 in Vitro and in Vivo

[Long-Term Results of Preoperative Regional Intraarterial Chemotherapy Against Colorectal Cancer].

Preoperative chemotherapy combined with PD-1 inhibitor in locally advanced operable or potentially resectable esophageal squamous cell carcinoma: A real world study.

First‐line programmed cell death 1 inhibitor plus chemotherapy vs. standard treatment in patients with recurrent or metastatic oral squamous cell carcinoma: A retrospective cohort study

[A clinicopathologic study on neoadjuvant chemotherapy in the treatment of non-small-cell lung cancer].

Pembrolizumab plus cetuximab with neoadjuvant chemotherapy for head and neck squamous cell carcinoma

Study of drug distribution in tissue during treatment with targeting and continuous interstitial chemotherapy in the oral squamous cell carcinoma

S-1 Plus Docetaxel and Cisplatin As an Induction Chemotherapy for Advanced Oral Squamous Cell Carcinoma: A Clinical Observation

EFFECT OF NEOADJUVANT CHEMOTHERAPY USING PACLITAXEL COMBINED WITH CARBOPLATIN ON ADVANCED NON-SMALL CELL LUNG CANCER

Surgery Combined with 125I Brachytherapy for Treatment of Carcinoma Ex Pleomorphic Adenoma of the Parotid Gland

Randomized controlled study on preoperative concurrent chemoradiotherapy versus surgery alone for esophageal squamous cell carcinoma